Brain zaps to fight weed addiction in schizophrenia?
NCT ID NCT04871048
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a non-invasive brain stimulation technique called tDCS can reduce cannabis use in people with schizophrenia. 110 motivated participants will receive either real or sham stimulation over 5 days. Researchers will track changes in cannabis consumption, cravings, and overall functioning over 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
transcranial direct current stimulation (tDCS) – a non-invasive brain stimulation device
What this could lead to
If it works, this could offer a new, drug-free way to help people with schizophrenia cut down or stop cannabis use, improving their overall health.
What could go wrong
This is an early exploratory study with only 110 people. The effects may be small or temporary, and not everyone may benefit. Brain stimulation can cause mild discomfort or headache.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
CH Le Vinatier Service universitaire d'addictologie de Lyon
NOT_YET_RECRUITINGBron, 69678, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CH Saint-Cyr-au-Mont-d'Or service de psychiatrie
NOT_YET_RECRUITINGSaint-Cyr-au-Mont-d'Or, 69450, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Pôle de Psychiatrie Neurologie et Rééducation
NOT_YET_RECRUITINGLa Tronche, 38700, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Clermont-Ferrand Service de Psychiatrie
NOT_YET_RECRUITINGClermont-Ferrand, 63000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Saint-Etienne
RECRUITINGSaint-Priest-en-Jarez, France
Contact
-
Centre Hospitalier Alpes Isère
NOT_YET_RECRUITINGSaint-Égrève, 38120, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Hospitalier Universitaire Service d'Addictologie et Pathologies Duelles
NOT_YET_RECRUITINGClermont-Ferrand, 63000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Service Hospitalo-Universitaire d'Addictologie CHU de Dijon
NOT_YET_RECRUITINGDijon, 21079, France
Contact Phone: •••-•••-•••• Email: •••••@•••••